secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2022-03-25T23:59:59+00:00
Accession:  0001193125-22-084200
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis prices public offering of 7.4M shares at $47/sh, raising $350M gross
----------------------------------------------------------------------------

- 7,446,809 shares at $47.00 per share; gross proceeds of $350 million.
- Net proceeds estimated at $330.2 million ($379.8 million if underwriters' option fully exercised).
- Offering expected to close March 28, 2022; underwriters have 30-day option for 1,117,021 additional shares.
- J.P. Morgan, Goldman Sachs, and Evercore acting as joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312522084200/0001193125-22-084200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312522084200/d268112d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-084200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer